Document is current
Any future updates will be listed below
-
Authors
Matsumoto, Toshio
Yamamoto, Kazuhiko
Takeuchi, Tsutomu
Tanaka, Yoshiya
Tanaka, Sakae
Nakano, Tetsuo
Ito, Masako
Tomomitsu, Tatsushi
Hirakawa, Akihiro
Soen, Satoshi
-
Funding
Funding for this research was provided by:
Chugai Pharmaceutical
- License Information
-
More Information
Article History
Received: 22 August 2019
Accepted: 8 February 2020
First Online: 5 March 2020
Compliance with ethical standards
:
: T.M. has received consulting fees from Chugai, Amgen Astellas Biopharma, Teijin Pharma, Daiichi-Sankyo and Asahi Kasei Pharma. K.Y. has received speaking fees, and/or honoraria from AbbVie, Astellas, AYUMI Pharma, Bristol-Myers Squibb, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Ono and UCB Japan. T.T. has received grants from Astellas, Chugai, Daiichi-Sankyo, Takeda, AbbVie, Asahi Kasei Pharma, Mitsubishi-Tanabe, Pfizer, Eisai, AYUMI Pharma, Nipponkayaku, Novartis and Shionogi. Honoraria from Astellas, AbbVie, AYUMI Pharma, Eisai., Gilead Sciences, GlaxoSmithKline, Sanofi., Taiho, Mitsubishi-Tanabe, Diaichi-Sankyo, Chugai, Taisho Pharma, Eli Lilly Japan, Novartis, Boehringer-Ingelheim, Nipponkayaku, Pfizer, Bristol–Myers Squibb, Janssen and UCB Japan. Y.T.　has received speaker fee and/or honoraria from Daiichi-Sankyo, Astellas, Chugai, Eli Lilly Japan, Pfizer, AbbVie, YL Biologics, Bristol-Myers Squibb, Takeda, Mitsubishi-Tanabe, Novartis, Eisai, Janssen, Teijin Pharma, and has received research grants from Asahi Kasei Pharma, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers Squibb, UCB Japan, Daiichi-Sankyo, Eisai and Ono. S.T. has received consulting fees, speaker fees, and/or honoraria from Amgen Astellas Biopharma, Astellas, Asahi Kasei Pharma, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly Japan, Ono, Pfizer, Taisho Toyama Pharma and Teijin Pharma. M.I. has received consulting fees, speaker fees, honoraria, and/or research funding from Chugai, Astellas, Asahi Kasei Pharma, Daiichi-Sankyo, Eli Lilly Japan, MSD, Ono and Pfizer. A.H. has received consulting fees, speaker fees, honoraria, and/or research funding from Astellas, Ono and Teijin Pharma. S.S. has received consulting fees, speaker fees, and/or honoraria from Asahi Kasei Pharma, Astellas, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly Japan, MSD, Ono, Pfizer, Takeda and Teijin Pharma. Other authors reported no conflict of interest related to this work.
